Moreover, treatment of MS patients with antibodies to IFN-γ for 5 consecutive days, which lowered IFN-γ levels to 70% of the starting level after one month and 85% of the starting level after 6 months, caused a significant decrease in the number of patients with disease progression during a 9–12 month period after treatment, as well as a significant increase in the time without progression, compared to the placebo group [47]. The gene discussed is IFNG; the disease is myeloid sarcoma.